Comparison of a rapid platelet function assay – Verify Now™ Aspirin – with whole blood impedance aggregometry for the detection of aspirin resistance

Dyszkiewicz-Korpanty, Anna M.; Kim, Anne; Burner, James; Frenkel, Eugene P.; Sarode, Ravindra

doi:10.1016/j.thromres.2006.11.006

Cited by 29 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aspirin effect 17, 21 (Table 2; Figure 3) was evaluated at Visit 2 by the change from baseline (Visit 1) in platelet aggregation induced by AA and collagen after 2 weeks of aspirin 81 mg/d. Both groups had near complete IPA to AA on aspirin (Table 3), group x time interaction p=0.78.…”

Section: Resultsmentioning

confidence: 99%

“…8, 9 These studies employed assays including optical aggregometry, multi-plate analyzers or platelet function analyzer (PFA)-100 which are sub-optimal for testing platelet function and the results may not be reproducible. 19, 21, 26 The WBPA method is superior to the these methods as it is more sensitive, evaluates platelets in a physiological milieu in the presence of red and white blood cells known to affect platelet function, and does not require centrifugation which can injure platelets. 26 As a result, knowledge gaps existed in our understanding of uremic platelet dysfunction from studies that were limited by lack of controls, or performed in uremic dogs 25 or ESRD.…”

Section: Discussionmentioning

confidence: 99%

“…Mixed model repeated measures (MMRM) analyses were used to compare WBPA induced by 0.5 mM AA, 2 μg/mL collagen and ADP responses (change) to aspirin and dual therapy between groups. 21 The model had group factor, treatment factor (repeated, pre- vs. post-), and interaction between group and treatment as covariates; the participant was modeled as a random effect. RPA was compared between-groups using the Fisher’s Exact test.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease

Jain

Adams‐Huet

et al. 2016

The American Journal of Cardiology

View full text Add to dashboard Cite

Thrombotic events while receiving anti-platelet agents (APA) are more common in individuals with vs. without chronic kidney disease (CKD). Data on anti-platelet effects of APA in CKD are scarce and limited by lack of baseline platelet function before APA treatment. We hypothesized individuals with stages 4–5 CKD vs. no CKD have higher baseline platelet aggregability and respond poorly to aspirin and clopidogrel. In a prospective controlled study, we measured whole blood platelet aggregation (WBPA) in 28 CKD and 16 non-CKD asymptomatic stable outpatients not on dual APA, frequency-matched for age, gender, obesity and diabetes mellitus. WBPA was re-measured after 2 weeks of each aspirin and aspirin plus clopidogrel. The primary outcome was percent inhibition of platelet aggregation (IPA) from baseline. The secondary outcome was residual platelet aggregability (RPA) (proportion with <50% IPA). Baseline platelet aggregability was similar between groups except adenosine diphosphate (ADP)-induced WBPA, which was higher in CKD vs. non-CKD; median (IQR) =13.5 (9.5, 16.0) vs. 9.0 (6.0, 12.0) Ω, p=0.007. CKD vs. non-CKD participants had lower clopidogrel-induced IPA, 38% vs. 72%, p=0.04. A higher proportion of CKD vs. non-CKD participants had RPA after clopidogrel treatment (56% vs. 8.3%, p=0.01). There were no significant interactions between CKD and presence of CYP2C19 polymorphisms for platelet aggregability in clopidogrel-treated participants. In conclusion, CKD vs. non-CKD individuals exhibited similar platelet aggregation at baseline, similar aspirin effects and higher residual platelet aggregability on clopidogrel, which was independent of CYP2C19 polymorphisms.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease

Jain

Adams‐Huet

et al. 2016

The American Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…It utilizes arachidonic acid as the agonist to measure platelet aggregation [5] and expresses aspirin resistance in aspirin reaction units (ARU) with values equal or superior to 550 defined as aspirin resistant. This test is easy to perform and does not require expertise in the specimen collection and processing.…”

mentioning

confidence: 99%

Aspirin resistance in hemodialysis patients

et al. 2010

View full text Add to dashboard Cite

“…A study of 6 major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease has been reported; the researchers found that these tests showed poor correlation and agreement. 10 A study 11 reported on the performance of the VerifyNow platelet function analyzer (Accumetrics, Inc, San Diego, CA) compared to the WB aggregation method. The researchers reported that VerifyNow was able to identify only aspirin effect and failed to detect aspirin nonresponsiveness, and suggested that the cut-off value needs to be readjusted compared with that of WB aggregation.…”

Section: Discussionmentioning

confidence: 99%

Aspirin Effects on Platelets Using Whole Blood Tested by Platelet Aggregometry: A Comparative Study for Test Validation in a Clinical Hemostasis Laboratory

Abdullah

Bakar

Zain

et al. 2013

Lab Med

View full text Add to dashboard Cite

Objective: Assessment on platelet responsiveness to aspirin may be required in selected clinical conditions. So far, no standardization in laboratory practices for aspirin assessment using whole blood (WB) platelet aggregation based test. A study for method validation was performed to investigate the aspirin effects on platelets by comparing with a reference method.Methods: Forty patients taking aspirin were analyzed using WB by conventional platelet aggregometer (Chrono-Log Model 500CA/560CA). Among these patients, nine of them had their platelet rich plasma (PRP) tested by the same analyzer (reference method). Another WB specimens from 25 patients were tested on both ChronoLog and Multiplate® (Dynabyte GmbH), which is a newer generation platelet function analyzer.Results: There were good and moderate agreements between WB on the Chronolog analyzer vs the reference method and WB on Chronolog vs WB on Multiplate® analyzers respectively.Conclusions: There are agreements between PRP and WB aggregation (WBA) methods in detecting aspirin effects on platelets. It is recommended that the test validation for the assessment of platelet responsiveness to aspirin is interpreted and correlated with the reference method preferably PRP.

show abstract

Comparison of a rapid platelet function assay – Verify Now™ Aspirin – with whole blood impedance aggregometry for the detection of aspirin resistance

Cited by 29 publications

References 18 publications

Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease

Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease

Aspirin resistance in hemodialysis patients

Aspirin Effects on Platelets Using Whole Blood Tested by Platelet Aggregometry: A Comparative Study for Test Validation in a Clinical Hemostasis Laboratory

Contact Info

Product

Resources

About